Genmab partner gets approval for lung cancer drug from Duobody platform
Janssen Pharmaceuticals has received approval for lung cancer drug Rybrevant
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN
On Friday, Genmab's partner Janssen Pharmaceuticals has been granted approval to launch lung cancer drug Rybrevant from the US Food and Drug Administration (FDA).
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
